Novo Nordisk

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novo Nordisk and other ETFs, options, and stocks.

About NVO

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. 

CEO
Maziar Mike Doustdar
CEOMaziar Mike Doustdar
Employees
68,794
Employees68,794
Headquarters
Bagsværd, Capital Region
HeadquartersBagsværd, Capital Region
Founded
1923
Founded1923
Employees
68,794
Employees68,794

NVO Key Statistics

Market cap
214.88B
Market cap214.88B
Price-Earnings ratio
14.12
Price-Earnings ratio14.12
Dividend yield
2.50%
Dividend yield2.50%
Average volume
20.08M
Average volume20.08M
High today
$48.82
High today$48.82
Low today
$47.87
Low today$47.87
Open price
$48.71
Open price$48.71
Volume
283.65K
Volume283.65K
52 Week high
$93.80
52 Week high$93.80
52 Week low
$43.08
52 Week low$43.08

NVO News

The Motley Fool 15h
Warning: This Skyrocketing Stock Has a Hidden Risk

Eli Lilly is leading the pack in the GLP-1 weight-loss drug market, but this good news won't last forever. Eli Lilly (LLY +0.23%) is winning the race in the GL...

Warning: This Skyrocketing Stock Has a Hidden Risk
Nasdaq 16h
Overlooked and Undervalued: Why Novo Nordisk Stock Deserves Attention

Key Points Novo Nordisk competes with Eli Lilly in the GLP-1 space. Novo Nordisk's recently launched GLP-1 pill could help reset the game. 10 stocks we like...

Overlooked and Undervalued: Why Novo Nordisk Stock Deserves Attention
The Motley Fool 17h
Is Viking Therapeutics Stock Really Going to $125?

Never say never. There's certainly a mathematical path to that level, if the company navigates it correctly. Most veteran investors can attest that, although t...

Is Viking Therapeutics Stock Really Going to $125?

Analyst ratings

53%

of 34 ratings
Buy
52.9%
Hold
38.2%
Sell
8.8%

More NVO News

Investor's Business Daily 22h
Hims & Hers Agrees To Buy Eucalyptus In $1.15 Bil Deal. Stock Rallies.

Hims & Hers Faces New Hurdle In Weight-Loss Brawl With Novo Nordisk 2/17/2026 Hims stock landed in hot water this month after Novo Nordisk slammed the teleheal...

Hims & Hers Agrees To Buy Eucalyptus In $1.15 Bil Deal. Stock Rallies.
The Motley Fool 1d
Forget Ozempic: This Obesity‑Drug Giant Is Grabbing the Biggest Slice of the GLP‑1 Gold Rush

Ozempic's rival is generating blockbuster revenue and gaining market share. Everyone has been talking about Ozempic in recent years. You may have seen the name...

Forget Ozempic: This Obesity‑Drug Giant Is Grabbing the Biggest Slice of the GLP‑1 Gold Rush
TipRanks 1d
Is HIMS Stock a Buy Ahead of Earnings? Options Traders Brace for 17% Price Swing

Hims & Hers (HIMS) will release its fourth-quarter fiscal 2025 results after market close on February 23. Analysts expect earnings to decline but sales to rise...

Simply Wall St 2d
Hims And Hers Faces GLP-1 Setback While Expanding Into Longevity Care

Hims & Hers Health (NYSE:HIMS) has halted its newly launched compounded GLP-1 weight loss pill only days after introducing it. The move follows a lawsuit from...

Hims And Hers Faces GLP-1 Setback While Expanding Into Longevity Care
TipRanks 3d
Novo Nordisk Expands Obesity Pipeline With New Phase 2 Trial for UBT251

Novo Nordisk (NVO) announced an update on their ongoing clinical study. The Novo Nordisk A/S study “A Study Investigating Safety, Tolerability and Efficacy of...

Simply Wall St 3d
Hims & Hers Health Is Down 5.5% After Novo Nordisk GLP-1 Lawsuit and FDA Scrutiny

In early February 2026, Novo Nordisk filed a patent infringement lawsuit against Hims & Hers over its compounded semaglutide weight-loss products, following an...

Hims & Hers Health Is Down 5.5% After Novo Nordisk GLP-1 Lawsuit and FDA Scrutiny
The Motley Fool 4d
Novo Nordisk's New Diabetes Drug Outshines Ozempic: Is The Stock a Buy?

Novo Nordisk's plan to gain ground in the GLP-1 space is slowly taking shape. Ozempic has been one of Novo Nordisk's (NVO +1.31%) main growth drivers for sever...

Novo Nordisk's New Diabetes Drug Outshines Ozempic: Is The Stock a Buy?

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.